Virinchi Ltd (VIRINCHI)

Information Technology · IT - Software · NSE · Updated 17 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹14.16 ↓ 55.02% (1Y)

🎯 Key Takeaways

Virinchi Ltd is in a strategic transition phase, shifting from a software-focused IT business toward healthcare services, as evidenced by the shareholder-approved acquisition of its healthcare division. The company has faced persistent profitability challenges, with negative ROE and ROCE, and declining margins in recent quarters.
Revenue grew 6.3% QoQ to ₹70 in Q1FY27.
⚠️ Persistent losses and negative operating margins despite revenue stabilization pose a material threat to sustainability.

Market Cap

₹160

P/B Ratio

0.34

ROE

-6.3%

ROCE

-0.1%

Debt/Equity

0.34

Promoter

39.5%

✨ Ask AI About VIRINCHI 📊 Interactive Charts

📖 The Story

Virinchi Ltd is in a strategic transition phase, shifting from a software-focused IT business toward healthcare services, as evidenced by the shareholder-approved acquisition of its healthcare division. The company has faced persistent profitability challenges, with negative ROE and ROCE, and declining margins in recent quarters. While revenue shows signs of stabilization, operational efficiency remains weak, and the business is undergoing structural realignment amid shareholder scrutiny and governance oversight.

📰 What's Happening

In August 2026, the board approved the unaudited Q1 FY27 financial results and reappointed Director Satyanarayana Vedula, signaling continuity in leadership during a period of strategic change. Shareholders approved the acquisition of the Primary and Secondary Healthcare Business Division via postal ballot on August 10, 2026, finalizing a key transformation step. Earlier, in July 2026, resolutions including material related party transactions and loans under Section 185 were passed with overwhelming approval, confirming governance compliance. The company also corrected errors in its revised audited financials for Q3FY26 and FY26 on July 14, 2026, requiring shareholder verification before investment decisions.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	80	62	77	66	70
Operating Profit	12	-4	12	-6	1
OPM %	14.9%	-5.8%	15.1%	-9.8%	2.0%
Net Profit	0	-14	2	-16	-2
EPS	₹0.04	₹-1.32	₹0.14	₹-1.38	₹0.04

The company's financial performance has been volatile, with margins under pressure — consolidated OPM turned negative in Q4FY26 (-9.8%) and remained low in Q1FY27 (2.0%), down from 15.1% in Dec 2025. Revenue declined from ₹80 crore in Jun 2025 to ₹62 crore in Sep 2025, though it modestly recovered to ₹66 crore in Mar 2026. Net losses widened in Q4FY26 (₹-16 crore) before narrowing slightly in Q1FY27 (₹-2 crore), suggesting temporary stabilization but no clear recovery trend. The correction of audited financials on July 14, 2026, indicates past accounting discrepancies, further undermining confidence in reported figures.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the disclosed filings, but actions suggest a strategic pivot toward healthcare services as a growth driver. The board's approval of the AGM date, financial reports, and director reappointment in August 2026 reflects procedural continuity amid transformation. The acquisition of the healthcare division, now shareholder-approved, positions the company for potential revenue diversification, though integration risks and profitability timelines remain unaddressed in public disclosures.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	102	103	103	109
Reserves	379	373	359	384
Borrowings	320	160	295	273
Total Liabilities	872	847	831	850
Fixed Assets	431	569	398	380
Investments	2	2	1	1
Total Assets	872	847	831	850

The balance sheet shows a mixed capital structure: equity has slightly increased to ₹109 crore (from ₹103 crore), while reserves declined from ₹384 crore to ₹359 crore, indicating possible utilization of reserves to offset losses. Borrowings rose to ₹273 crore from ₹295 crore, suggesting active deleveraging or reduced reliance on debt. Total assets grew to ₹850 crore from ₹831 crore, reflecting asset base expansion, likely tied to the healthcare acquisition. The company appears to be managing capital prudently, with a focus on reducing debt and preserving equity, though profitability pressures may constrain long-term investment capacity.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+84
Investing	-78
Financing	-19
Net Cash Flow	-12

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	37.5%	40.1%	39.5%
FII	0.1%	0.1%	0.0%
DII	0.0%	0.0%	0.0%
Public	51.2%	49.0%	49.0%
# Shareholders	38,947	37,671	37,033

Promoter holding has fluctuated significantly, dropping from 40.1% in Q4FY26 to 39.46% in Q1FY27, while public holding rose to 48.99% from 48.99% (stable), but institutional interest remains negligible — FII and DII holdings are near zero. The number of public shareholders increased slightly to 37,033 from 37,671, indicating retail stability. No insider selling or significant institutional accumulation is evident, suggesting limited confidence from large investors. The lack of FII/DII activity may reflect low liquidity or skepticism about the company’s turnaround prospects.

⚖️ Peer Comparison — IT - Software

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
TCS	7.93 L Cr	15.9	63.2%	46.7%	0.00
INFY	4.30 L Cr	14.3	44.9%	32.7%	0.00
HCLTECH	3.40 L Cr	19.4	31.6%	23.2%	0.00
WIPRO	1.65 L Cr	13.2	18.1%	15.1%	0.19
TECHM	1.52 L Cr	26.8	24.8%	17.4%	0.00
LTM	1.26 L Cr	24.0	30.5%	21.6%	0.00
OFSS	1.00 L Cr	29.4	60.3%	43.6%	0.00
PERSISTENT	85,675	44.1	32.7%	24.5%	0.00
COFORGE	77,956	35.8	25.6%	20.7%	0.04
MPHASIS	44,263	23.1	22.3%	17.8%	0.17

🔗 Peer Stock Analyses

TCS INFY HCLTECH WIPRO TECHM

⚠️ Risk Factors

1. Persistent losses and negative operating margins despite revenue stabilization pose a material threat to sustainability. 2. The healthcare acquisition, while approved, introduces integration and execution risks with no clear timeline for profitability. 3. Governance concerns were highlighted by the correction of audited financials, raising questions about accounting rigor. 4. Heavy reliance on promoter-held shares (nearly 40%) creates vulnerability to concentration risk, especially if promoter stakes are pledged or subject to future dilution.

📋 Recent Filings

🧠 Analyst's Read

Virinchi Ltd is navigating a high-stakes transformation with limited visibility into execution timelines or financial recovery. Investors should monitor the integration of the healthcare division, upcoming AGM outcomes, and any future guidance from management. The absence of institutional interest and volatile promoter holding warrant caution. The company’s turnaround hinges on operational improvement and margin recovery, which remain unproven.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIRINCHI

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIRINCHI files new disclosures

Track VIRINCHI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIRINCHI — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd